Showing 2411-2420 of 2656 results for "".
- EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-retina-society-scientific-meeting/2476859/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 5
- CorNeat Vision Completes Preclinical Phase For Synthetic Cornea and Scleral Patchhttps://modernod.com/news/corneat-vision-completes-preclinical-phase-for-synthetic-cornea-and-scleral-patch/2479538/CorNeat Vision announced it has completed the preclinical stage of its cornea implant (CorNeat KPro/Keratoprosthesis) and the first synthetic, non-degradable scleral patch (CorNeat EverPatch). The company’s solutions, which also include a glaucoma drainage device, the CorNeat eShunt, will b
- Oculus Release Myopia Master for Myopia Managementhttps://modernod.com/news/oculus-release-myopia-master-for-myopia-management/2476839/Oculus has introduced the Myopia Master, a device designed to combine all the important measurement methods of myopia management: axial length, refraction values, and the central corneal radii. The Oculus Myopia Master creates a myopia report for each patient, giving due consideration to s
- Oklahoma Judge Orders Johnson & Johnson to Pay $572 Million in Bellwether Opioid Casehttps://modernod.com/news/oklahoma-judge-orders-johnson-johnson-to-pay-572-million-in-bellwether-opioid-case/2476824/A US judge has ruled that Johnson & Johnson must pay $572 million for contributing to an opioid crisis in Oklahoma, where the state’s attorney general had been seeking damages of more than $17 billion. District court Judge Thad Balkman said “the state met its burden that
- AcuFocus Completes Study Enrollment for U.S. IDE Clinical Trial of IC-8 Lenshttps://modernod.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/AcuFocus announced that it has completed enrollment in its pivotal US investigational device exemption (IDE) study of the company’s IC-8 small aperture IOL. FDA granted approval of the company’s IDE on November 21, 2018, and the Investigational Review Board approved the study just 5
- Lineage Cell Therapeutics Launches New Corporate Brandhttps://modernod.com/news/lineage-cell-therapeutics-launches-new-corporate-brand/2479549/Lineage Cell Therapeutics, previously BioTime, announced the effective change of its corporate name and formal launch of its new corporate brand. In connection with the launch, the company’s NYSE American ticker symbol has changed to “LCTX” and will be effective at the open of t
- BioTime Announces Name Change to Lineage Cell Therapeuticshttps://modernod.com/news/biotime-announces-name-change-to-lineage-cell-therapeutics/2479562/In a move to reflects the company’s commitment to becoming a leading cell therapy company, BioTime announced it is launching a new corporate brand, including a change of its corporate name to Lineage Cell Therapeutics, effective August 12, 2019. In connection with the launch, the com
- Bausch + Lomb Showcases New Retina Innovations at In-Booth Wet Lab at ASRShttps://modernod.com/news/bausch-lomb-showcases-new-retina-innovations-at-in-booth-wet-lab-at-asrs/2476764/Bausch + Lomb announced that it will showcase the company’s latest retina innovations, including the 23-gauge Bi-Blade dual port vitrectomy cutter and the FreeFlow infusion system, at a wet lab located in the Bausch + Lomb booth (#606) during the Annual Meeting of the American Society of Retina S
- ProQR: RNA Therapy Has Potential to Restore Vision in Patients With Usher Syndromehttps://modernod.com/news/proqr-rna-therapy-has-potential-to-restore-vision-in-patients-with-usher-syndrome/2479570/Usher syndrome is an inherited retinal degeneration that affects hearing, balance, and vision. Usher syndrome caused by USH2A mutations is one of the most common causes of retinitis pigmentosa (RP) with syndromic features. Currently there is no treatment for the sensory deficits caused by Usher s
- VSP Global Enters Into Definitive Agreement To Acquire Visionworkshttps://modernod.com/news/vsp-global-enters-into-definitive-agreement-to-acquire-visionworks/2476699/VSP Global announced that it has entered into a definitive agreement to acquire San Antonio, Texas-based Visionworks, which has more than 700 stores in 40 states. The Visionworks acquisition will be the single largest VSP network investment in the company’s